TXMD241018P1000
- 0.01
- 0.000.00%
TherapeuticsMD Newsroom
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
Express News | Corrected-TherapeuticsMD Inc: Qtrly Shr (Not 'eps') Loss From Cont Ops $0.09
TherapeuticsMD | 10-Q: Q2 2024 Earnings Report
Express News | TherapeuticsMD Inc: Qtrly EPS Loss From Cont Ops $0.09
Express News | TherapeuticsMD Inc: Continues to Evaluate a Variety of Strategic Alternatives
TherapeuticsMD 2Q License Rev $234,000
TherapeuticsMD 2Q Loss Cont Ops 9c/Shr
Express News | TherapeuticsMD Q2 Operating Expenses USD 2.7 Million
Express News | TherapeuticsMD Announces Second Quarter 2024 Financial Results
U.S. Menopause Market Trends Analysis Report 2024-2030 Featuring Pfizer, Novo Nordisk, TherapeuticsMD, Bayer, AbbVie, Pure Encapsulations, and PADAGIS
Nektar, Verastem Among Healthcare Additions in Russell Microcap; Assertio, Sangamo Removed
TherapeuticsMD (TXMD.US): The 2024 Q1 financial report achieved revenue of US$313,000, previous value of US$416,000; earnings per share were -0.07 USD, prior value of -0.24 USD.
TherapeuticsMD (TXMD.US): The 2024 Q1 financial report achieved revenue of US$313,000, previous value of US$416,000; earnings per share were -0.07 USD, prior value of -0.24 USD.
TherapeuticsMD | 10-Q: Q1 2024 Earnings Report
TherapeuticsMD Q1 EPS $(0.07) Up From $(0.24) YoY
TherapeuticsMD 1Q Cont Ops Loss/Shr 7c >TXMD
Press Release: TherapeuticsMD Announces First Quarter 2024 Financial Results
323 types of medicines are in urgent need! The usa is currently facing the largest-ever "drug shortage"...
The United States seems to be facing an unprecedented widespread 'drug shortage'...
Therapeutics MD Reports FY Results
TherapeuticsMD: Evaluation of Strategic Alternatives Continues >TXMD
TherapeuticsMD 2023 Cont Ops Loss/Shr 74c >TXMD